ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "infliximab and safety"

  • Abstract Number: 1549 • 2017 ACR/ARHP Annual Meeting

    A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis:  6 – Months Clinical Outcomes from the Czech Biologic Registry Attra

    Šárka Forejtová1, Jakub Zavada1, Lenka Szczukova2, Katerina Jarosova1, Tom Philipp3 and Karel Pavelka4, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, 2Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic, 3Department of Rheumatology and Physiotherapy, Thomayer Hospital, Prague, Praha 4, Czech Republic, 4Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: A non-medical switch from originator (INX, Remicade) to biosimilar infliximab (CT-P13, Remsima) was conducted in 36 patients with ankylosing spondylitis (AS) in one clinical…
  • Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium

    Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades

    Jennifer Rammel1, Patricia Rosillo1, Tiphanie Vogel2 and Marietta de Guzman3, 1Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 2Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, 3Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
  • Abstract Number: L15 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13

    Won Park1, Pedro Miranda2, Marek Brzosko3, Piotr Wiland4, Sergio Gutierrez-Ureña5, Helena Mikazane6, Yeon-Ah Lee7, Svitlana Smiyan8, Mie-Jin Lim1, Vladimir Kadinov9, Carlos Abud-Mendoza10, YoungKi Son11, Dae-Hyun Yoo12 and Jürgen Braun13, 1Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, 2Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, 3Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, 4Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 5Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico, 6Outpatient Clinic 'ORTO', Riga, Latvia, 7Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, 8Municipal Institution of Ternopil Regional Council "Ternopil University Hospital", Ternopil, Ukraine, 9Multiprofile Hospital for Active Treatment 'Sv. Marina', Varna, Bulgaria, 10Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosyi, Mexico, 11CELLTRION, Incheon, South Korea, 12Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 13PsAID taskforce, EULAR, Zurich, Switzerland

    Background/Purpose: CT-P13 is an infliximab (INX) biosimilar recently approved by the European Medicine Agency. PLANETAS was a 54-week (wk) randomized double-blind parallel group multicenter Phase…
  • Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting

    Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections

    Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies